Best selling immunology drugs by revenues | Top immunology drugs | 2024 | iPharmaCenter
Top selling cancer drugs of 2024 | Best selling cancer drugs | Top cancer drugs by revenues in 2024 | iPharmaCenter
Top pharmaceutical companies by revenues in 2024 | Biggest Pharma of 2024 | Top Pharma profits | iPharmaCenter
Expected | Best selling drugs of 2024 | Top selling drugs of 2024 | iPharmaCenter
LEQEMBI (Lecanemab) Receives Approval in Israel for Treating Alzheimer's Disease | iPharmaCenter
Pharmaceutical deals | Acquistions | 2024 | iPharmaCenter
Lilly's Tirzepatide Shows Promise in MASH Treatment, Achieves Notable Results in Phase 2 Study | iPharmaCenter
Top selling drugs of 2024 | Best selling drugs of 2024 | iPharmaCenter
European Commission Approves Opdivo with Cisplatin and Gemcitabine for First-Line Treatment of Advanced Urothelial Carcinoma | iPharmaCenter
Merck Announces Success in Phase 3 KEYNOTE-522 Trial for High-Risk Early-Stage Triple Negative Breast Cancer (TNBC) | iPharmaCenter
Australia Healthcare News | Media | Updates
India Drug Approvals | 2024 | CDSCO | News | Updates | Media | iPharmaCenter
CMS aims to address kidney transplant issues with Enhanced Access to Organ Transplant initiative | iPharmaCenter
HHS Unveils Fresh Data Revealing Over 10 Million Medicare Beneficiaries Received Complimentary Vaccines Under President's Initiative to Curb Inflation | US Healthcare News | iPharmaCenter
Top 10 best selling cancer drugs in 2023 | Top cancer drug makers | iPharmaCenter
World Congress of Nephrology (WCN) | News | Updates | 2024 | iPharmaCenter
Giant cell arteritis | Rinvoq | News | Media | iPharmaCenter
FDA Devices Approval | 2024 | Abbott News | iPharmaCenter
Inflammatory bowel disease | Crohn's disease | Ulcerative colitis | News | Updates | 2024 | iPharmaCenter
Japan Drug Approvals | March 2024 | PMDA | MHLW Updates | iPharmaCenter
FDA approved Orchard Therapeutics' Lenmeldy for juvenile metachromatic leukodystrophy | FDA Approvals | News | iPharmaCenter
CHMP Positive Opinions | February | 2024 | iPharmaCenter
Best selling diabetes mellitus drugs | 最畅销的糖尿病药物 | medicamentos para la diabetes mellitus más vendidos | सर्वाधिक बिकने वाली मधुमेह दवाएँ | iPharmaCenter | 2024
Japan Drug Approvals | 日本の医薬品承認 | ニュース | 日本のニュース速報 | 健康管理 | 2024 | iPharmaCenter
Express-Scripts | Pharmacy Benefit Manager | News | Updates | 2024 | US Healthcare | iPharmaCenter
Top pharma companies by revenues in 2023| Best Selling Drugs of 2023 |Top 20 pharma companies | iPharmaCenter
Deals and Acquisitions | 2023 | Pharma | News | Healthcare | iPharmaCenter
Top CMS Pharmaceutical Expenditures: Analyzing High-Expenditure Medications
Best selling drugs of 2023 | Top 10 drugs by revenues | Best selling pharmaceuticals | iPharmaCenter
Depression | How common is depression? How to deal with depression? | iPharmaCenter
Radioligand therapy news | Updates | iPharmaCenter
IgA nephropathy (IgAN) | News | Updates | Blogs | iptacopan | iPharmaCenter
Cancer News | Cancer Updates | Recent updates in cancer treatment, diagnosis | iPharmaCenter
Top selling immunology drugs | Top 10 immunology drugs by revenues | iPharmaCenter
Chronic rhinosinusitis with nasal polyps | News | Updates | iPharmaCenter
PCSK9 inhibitors | Heart Failure News | Updates | iPharmaCenter
Chronic spontaneous urticaria | News | Updates |
10 Most Expensive Drugs | 2023 | Pharmaceuticals | iPharmaCenter
Multiple Sclerosis | News | Blogs | Updates | 2023
Pharmaceutical Companies Deals and acquisitions | Sanofi | Amgen | Pfizer | 2022 | iPharmaCenter
How is AbbVie bracing for the impact of Humira’s biosimilars? | iPharmaCenter
TOP PHARMACEUTICAL COMPANIES BY REVENUES IN 2022
Top-selling cancer drugs | 2022 | 2023 | Best cancer products | iPharmaCenter
Top 5 drug launches in 2023 that has potential to be blockbusters | iPharmaCenter
Expected best selling drugs of 2023
Access to Medicines | 2021 | 2022 | News | iPharmaCenter | GSK tops list
Multiple Myeloma | News | Blogs | FDA and EMA approvals | Updates on clinical guidelines
Merck and Moderna agreed to develop and commercialize a cancer vaccine | iPharmaCenter
Sanofi gave a statement on the U.S. Zantac litigation | iPharmaCenter
AbbVie's JAK inhibitor, Rinvoq, was approved for UC and nr-axSpA in Europe | iPharmaCenter